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Abstract
Background: To investigate the feasibility of DWI in evaluating early therapeutic response of uterine cervical cancer
to concurrent chemoradiation (CCR) and establish optimal time window for early detection of treatment response.
Methods: This was a prospective study and informed consent was obtained from all patients. Thirty-three patients
with uterine cervical cancer who received CCR underwent conventional MRI and DWI examinations prior to therapy
(base-line) and at 3 days (postT1), 7 days (postT2), 14 days (postT3), 1 month (postT4) and 2 months (postT5) after
the therapy initiated. Tumor response was determined by comparing the base-line and postT5 MRI by using RECIST
criterion.
Results: Percentage ADC change (γADC) of complete response (CR) group at each follow up time was greater than that
of partial response (PR) group, and the differences were significant at postT3 (p = 0.007), postT4 (p = 0.001), and postT5
(p = 0.019). There was positive correlation between γADC at each follow-up time and percentage size reduction at postT5.
The day of 14 after the therapy initiated can be considered as the optimal time for monitoring early treatment response
of uterine cervical cancer to CCR, and the representative and sensitive index was γADC. With the cut-off value of 35.4 %,
the sensitivity and specificity for prediction of CR group were 100 % and 73.1 %, respectively.
Conclusions: It is feasible to use DWI to predict and monitor early treatment response in patients with uterine cervical
cancer that undergoing CCR, and optimal time window for early detection of tumor response is the day of 14 after
therapy initiated.
Background
Uterine cervical cancer remains to be the second most
prevalent gynaecological tumors worldwide [1]. Recently,
cisplatin-based concurrent chemoradiation (CCR) has
been established as being more effective than radiation
therapy (RT) alone because chemotherapy has been
shown to increase the sensitivity of tumor cells to radi-
ation and to control both local and systemic disease
manifestations [2]. However, not all tumors of the same
pathological type and FIGO stage will follow the same
course of disease; individual responses to CCR have been
shown to vary significantly. Therefore, precise assessing
tumor response before or at an early stage of CCR is
important for treatment planning and for determining
the prognosis.
Tumor response to therapy is conventionally assessed
by changes in tumor size according to the Response
Evaluation Criteria in Solid Tumors (RECIST) using com-
puted tomography (CT) or Magnetic resonance (MR) im-
aging. Unfortunately, the information from post-therapy
imaging after treatment completion usually comes too late
to realistically impact patient management [3]. If therapy
failure can be predicted effectively and as early as possible
in the initial course of treatment, it will provide a window
of opportunity to change the initial therapy approach up-
front and clinical management can be profoundly im-
pacted in the individual patient [3]. Given this difficulty,
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increasing demands are placed on imaging modalities
to provide an early and reliable response marker which
would have great clinical importance for uterine cer-
vical cancer patients to cease ineffective treatment and
to avoid delays in starting alternative, potentially more
effective treatments.
Diffusion-weighted MR imaging (DWI) is a functional
MR imaging technique that can explore the random dif-
fusion motion of water molecules in vivo [4]. Previous
studies in a variety of tumor types have suggested that
quantitative interpretation of apparent diffusion coeffi-
cient (ADC) can be used as a biomarker for response to
treatment [5–9]. To date, a few clinical studies on the
usefulness of DWI as a measurement of treatment re-
sponse in uterine cervical cancer have been reported
[10–13]. However, systematic investigation to evaluate
the optimal time window to detect early response of
tumor to CCR is lacking. The present study was there-
fore designed to systematically analyze dynamic changes
of ADC after initiation of CCR, and determine whether
ADC measurements of uterine cervical cancer before
and after early initiation of CCR can be used to follow
treatment response, in particular, to provide a time-
window of early detection of response to CCR.
Methods
Patient population
Our study received institutional ethics committee ap-
proval (Tianjin Medical University General Hospital)
and written informed consent was obtained from all pa-
tients. Forty-five patients with biopsy-proven uterine
cervical cancer, who planned to receive CCR, were pro-
spectively recruited to this study. Inclusion criteria con-
sisted of [a] histologically (biopsy) proven squamous cell
carcinoma of uterine cervix before the first MR examin-
ation, and the time interval between biopsy and base-
line MR examination did not exceed 1 month; [b] FIGO
stage based on clinical examination ranges from II to IV;
[c] no previous radiation or CCR treatment for uterine
cervical cancer; [d] treatment consisting of radiotherapy
and cisplatin-based chemotherapy; [e] no contraindica-
tions for MR examination. Exclusion criteria consisted of
[a] unable to complete the full course of treatment, [b]
time interval between base-line MRI and start of treat-
ment is more than a week, [c] fail to complete the follow-
up MRI examinations on time. All participants were
scheduled to receive six MR examinations: before CCR
(base-line), at 3 days (postT1), 7 days (postT2), 14 days
(postT3), 1 month (postT4) and 2 months (postT5) after
therapy initiated. 12 patients were excluded from the
study because of unable to complete the full course of
treatment (5 patients) or fail to complete the follow-up
MRI examinations on time owing to patient incompli-
ance (7 patients). Finally, 33 female patients (mean age
53.6 years; age range, 36–75 years) with uterine cervical
cancer enrolled in this study.
Treatment
All patients were scheduled to undergo external beam
radiation therapy (EBRT) of the pelvis and intracavitary
brachytherapy (ICBT). Treatment was composed of
2 days per week of brachytherapy in the form of intra-
cavitary (60 Gy/12 fractions), and then 3 days per week
of pelvic external beam radiotherapy (42 Gy/21 fractions
to point B), accompanied with cisplatin chemotherapy at
a dose of 40 mg/m2 during the intervening weekends.
MR examination
All MR examinations were performed using a 1.5-T unit
(Twin Excite, GE Healthcare, USA) with a torso phased-
array body coil. Before DWI, conventional T2-weighted
fast spin-echo in the sagittal and transverse planes (TR/
TE, 4,000 ms/85 ms; matrix size, 320 × 224; band width,
31.25 Hz/pixel; field of view, 36 cm; number of excita-
tions, 2; slice thickness, 6 mm; gap, 1 mm), T2-weighted
fast spin-echo with fat suppression in the transverse
plane (the parameters were the same as for the T2-
weighted image) and T1-weighted spin-echo in the
transverse plane (TR/TE, 500 ms/20 ms; matrix size,
320 × 160; band width, 31.25 Hz/pixel; field of view,
36 cm; number of excitations, 2; slice thickness, 6 mm;
gap, 1 mm) were obtained.
Diffusion-weighted MR images were acquired using a
non-breath-hold single-shot spin-echo echo-planar im-
aging (EPI) sequence and array spatial sensitivity encoding
technique (ASSET) in the transverse plane (TR/TE,
4,000 ms/58.5 ms for b values of 0 and 1000 s/mm2;
matrix size, 128 × 128; field of view, 36 cm; number of ex-
citations, 4; slice thickness, 6 mm; gap, 1 mm; R factor, 2;
phase-encoding direction, anteroposterior). The diffusion-
weighting gradients were applied in all three orthogonal
directions. The scanning time of DWI was 1 min and 4 s.
MR image analysis
MR images were analyzed by two radiologists who per-
formed tumor ADC measurements and longest tumor
diameter measurement on the pre- and post-CCR im-
ages independently. The readers were blinded to each
other’s results. The longest tumor diameter was mea-
sured using the transverse plane on T2-weighted images.
ADC maps were calculated on a pixel-by-pixel basis by
using built-in software (AW4.3 Functool; GE Health-
care). For ADC calculation, up to three slices depicting
the largest tumor diameter were selected and then
tumor margins were free-hand delineated on DW im-
ages. In each slice a region of interest (ROI) was delin-
eated according to the tumor geometry. The border of
the ROI was placed in the tumor periphery close to the
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tumor margin in order to encompass as much of the
tumor as possible with exclusion of hemorrhagic or nec-
rotic areas. If the residual tumor was tiny and covered
less than three slices, the ROIs were assessed twice in
the same site by each experienced radiologist. In case of
invisible residual tumors on MR images after completion
of therapy at T5, the ROI was drawn on the same area
where tumors were identified at base-line MR images.
Mean ADC value was calculated by average for each
tumor.
The ADC changes (γADC) (as a percentage) for each
lesion between the base-line and follow-up time points
were calculated using the formula:
γADC ¼ ADCF−ADCBð Þ=ADCB  100;
where ADCB represents pretreatment ADC values, and
ADCF represents the post-treatment ADC values after
CCR initiated.
The longest tumor diameter changes (γD) (as a per-
centage) for each lesion between the base-line and
follow-up time points were calculated using the formula:
γD ¼ DB−DFð Þ=DB  100;
where DB represents pretreatment longest tumor diam-
eter, and DF represents the post-treatment longest tumor
diameter after CCR initiated.
Treatment outcome analysis
According to Response Evaluation Criteria in Solid
Tumors (RECIST 1.1), response to treatment was deter-
mined by comparing the base-line MRI and follow-up
MRI at 2 months after the therapy initiated [14]. Complete
response (CR) was concluded if there was no residual
tumor on T2-weighted images; partial response (PR) was
concluded if the longest diameter of the tumor was less
than 70 % of the original size; the disease was determined
to be stable (SD) if there was neither sufficient shrinkage
to qualify for partial response nor sufficient increase to
qualify for progressive disease; and progressive disease
(PD) was concluded if there was at least a 20 % increase in
the longest diameter of tumor, taking as reference the lon-
gest diameter recorded pre-treatment.
Statistical analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS, version 13.0).
Intra-class correlation (ICC) of coefficient between two
readers was calculated. Multiple comparisons of con-
tinuous data were performed by Randomized blocks
analysis of variance. In order to test differences between
two independent groups, statistical comparisons were
made using Student’s t-test. Pearson correlation coeffi-
cient was used in order to test independence between
variables. A ROC analysis was performed to determine
the optimal time window for early detection of tumor
response to CCR. From the ROC analysis, Youden’s
index was used in determining the optimal threshold
value. The resulting threshold values were then used to
calculate the sensitivity and specificity. A level of p value
<0.05 was regarded as statistically significant.
Results
The agreement of two readers was excellent with an ICC
of 0.82 for the assessment of tumor diameter and 0.85
for ADC values.
Patient diagnosis and outcome
33 female patients with squamous cell carcinoma of
uterine cervix were enrolled in this study, including 10
cases of IIb, 1 case of IIIa and 22 cases of IIIb. Mean
pretreatment diameter of tumor was 45.6 mm (range,
26.7–89.6 mm). Standard radiographic follow up of
tumor response classified 7 patients as CR (Fig. 1), 26
patients as PR.
Comparison of base-line ADC and tumor diameter between
CR and PR
The base-line tumor diameter of group PR was slightly
larger than group CR, but there was no significant differ-
ence between them (t = −0.443, p = 0.661). The base-line
ADC value of group CR was significantly lower than that
of PR (t = −2.991, p = 0.007) (Table 1).
The mean base-line ADC value of all tumors was
(0.852 ± 0.081) × 10−3 mm2/s, mean base-line tumor diam-
eter was (45.624 ± 14.778) mm and mean percentage size
reduction of tumor at postT5 was (65.9 ± 20.4) %. No cor-
relations were noted between the pre-treatment tumor
diameter and pre-treatment ADC value (Pearson coeffi-
cient, −0.317; p = 0.072). The percentage size reduction of
tumor at postT5 was significantly and inversely correlated
with base-line ADC value (Pearson coefficient, −0.351; p
= 0.045); while there was no significant correlation be-
tween the percentage size reduction of tumor at T5
and base-line tumor diameter (Pearson coefficient,
−0.119; p = 0.508).
Comparison of pre- and post-treatment ADC and tumor
diameter
For group CR, the ADC value increased gradually after
therapy initiated, and pre-treatment and post-treatment
ADC value varied significantly (p < 0.001). Statistical dif-
ference was observed between either two times (p < 0.001)
except for postT1 and postT2 (P = 0.065).
For group PR, the ADC value increased gradually
after therapy initiated, and pre-treatment and post-
treatment ADC value varied significantly (p < 0.001).
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Statistical difference was observed between either two
times (p < 0.001).
The longest tumor diameter decreased gradually for both
group CR and PR, and pre-treatment and post-treatment
tumor diameter varied significantly (p < 0.001; p < 0.001).
Tumor diameter shrinkage that achieved statistical differ-
ence at the earliest follow up time was T4 compared with
pre-treatment tumor diameter for both CR and PR group.
Fig. 1 MRI and DWI images of uterine cervical cancer in group CR ((a–b), before CCR; (c–d), postT1; (e–f), postT2; (g–h), postT3; (i–j), postT4; (k–l),
postT5). At base-line MRI, axial T2-weighted images (a) show a hyperintense tumor with well-defined margin before therapy. At postT1 (c) and
postT2 (e), no significant change in size was shown. At postT3 (g), tumor showed a decrease in size. At postT4, tumor reduced in size markedly
(i). At postT5, no residual tumor could be seen on T2-weighted images (k). The ADC values were 0.816 × 10−3 mm2/s at base-line (b),
0.935 × 10−3 mm2/s at postT1 (d), 1.090 × 10−3 mm2/s at postT2 (f), 1.110 × 10−3 mm2/s at postT3 (h),1.280 × 10−3 mm2/s at postT4 (j),
and 1.350 × 10−3 mm2/s at postT5 (l)
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Comparison of ADC and γADC during treatment between
CR and PR
The ADC value for both group CR and PR increased to
different extents after the initiation of CCR. For group
CR, ADC values increased steadily from postT1 to
postT2, and then increased sharply; while, gradual in-
crease was found from postT1 to postT5 for group PR.
There was no significant difference of ADC value be-
tween group CR and PR at either follow up time dur-
ing therapy (Table 2). γADC of group CR at all follow
up time was greater than that of group PR, and the
differences were significant at postT3 (P = 0.007),
postT4 (P =0.001), and postT5 (p = 0.019) (Fig. 2).
At postT1, postT2, postT3, postT4, and postT5 there
was linear positive correlation between γADC and the
percentage size reduction of tumor at postT5 (p = 0.014,
p = 0.026, p < 0.001, p = 0.001, p = 0.012). No significant
correlation was found between ADC value at either follow
up time and the percentage size reduction of tumor at
postT5 (p = 0.875, p = 0.952, p = 0.187, p = 0.211, p = 0.240).
As the difference of γADC between CR and PR group
achieved significance as early as 14 days after CCR initi-
ated, and meanwhile γADC of cervical cancer had a sig-
nificant linear correlation with tumor response at that
time; the day of 14 after the therapy initiated can be
used as the optimal time window for early detection of
tumor response to CCR, and the representative and sen-
sitive index for evaluation therapeutic efficacy was
γADC. A cut-off value was calculated using γADC by
ROC analysis (Fig. 3). With the percentage ADC change
of 35.4 %, the sensitivity and specificity for predicting a
MRI complete response were 100 % and 73.1 % respect-
ively (95 % confidence interval, 0.708–0.974) and the
area under the ROC curve was 0.841.
Comparison of tumor diameter and γD during treatment
between CR and PR
The tumor diameter decreased gradually for both group
CR and PR, but there were no significant differences of
tumor diameter or γD between them at either follow up
time during therapy (Tables 3 and 4).
Discussion
Conventional imaging procedures such as CT and con-
ventional MRI evaluate the tumor response by measur-
ing changes in tumor size caused by therapy, and it was
generally accepted that a decrease in tumor size corre-
lated with treatment effect. However, changes in mor-
phological parameters such as volume and diameter of
tumor have been used with limited success, since lesions
do not substantially decrease in size in short-time after
CCR and these imaging techniques may be limited in
providing clinically satisfactory information about the
extent of tumor necrosis, which is the main indicator of
tumor cell death. Hence, there is need for new imaging
modalities which can be used to satisfy the increasing
demands of pretreatment prediction and early post-
treatment monitoring and particularly, establish the op-
timal time window for early detection of tumor response
to CCR [15].
DWI is a functional MR technique that has become a
constant additive to morphologic imaging and its role
has been already studied extensively [16]. It can be per-
formed on most modern MRI machines without any
additional new equipment or intravenous contrast agents
[17]. It has become increasingly important in the assess-
ment of tumors and evaluation of response during
follow-up with various treatment modalities and it has
been recommended as a cancer imaging biomarker in
the clinical trials by the national cancer institute (NCI)
of USA [18]. By exploiting information about changes in
proton mobility caused by the alteration of tissue cellu-
larity and the integrity of the cellular membrane, tortu-
osity of extracellular space, and viscosity of fluids due to
pathologic processes, DWI provides a tissue contrast
that is different from that made with conventional T1-
weighted (T1WI) and T2-weighted images (T2WI). It
can be used to characterize highly cellular and acellular
regions of tumors, distinguish cystic from solid regions,
as well as the change in cellularity within the tumor
over time [19–21].
Several studies have confirmed that cellular tumors
with low pre-treatment ADC values show a better re-
sponse to various therapies than those with high pre-
treatment ADC values [22, 23]. In this study, we found
that the pre-treatment ADC value of group CR was sig-
nificantly lower than that of group PR, in accordance
with results mentioned above; moreover, pretreatment
ADC value inversely correlated with the response to
Table 2 Comparison of ADC value during treatment between
CR and PR
CR(10−3 mm2/s) PR(10−3 mm2/s) t P
PostT1 0.958 ± 0.073 0.987 ± 0.096 −0.719 0.477
PostT2 1.036 ± 0.118 1.062 ± 0.110 −0.552 0.585
PostT3 1.213 ± 0.981 1.154 ± 0.131 1.094 0.282
PostT4 1.379 ± 0.132 1.283 ± 0.141 1.621 0.115
PostT5 1.507 ± 0.132 1.425 ± 0.140 1.389 0.175






CR (n = 7) 0.810 ± 0.015 43.400 ± 7.465
PR (n = 26) 0.863 ± 0.088 46.223 ± 16.260
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treatment. One possible explanation is that necrotic tu-
mors, which are characterized by a breakdown of cellu-
lar membrane, thereby allowing free diffusion and an
increase of diffusing molecules, resulting in higher ADC
values, are frequently hypoxic, acidotic, and poorly per-
fused, leading to diminished sensitivity to chemotherapy
and radiation therapy [17]. Furthermore, the distribution
of chemotherapeutic agents in necrotic tumors may be
less efficient because of insufficient vascularity. There-
fore, it may be hypothesized that patients with necrotic
areas in their tumors, and thus high pretreatment ADC
values, would have a worse treatment outcome. These re-
sults demonstrate the feasibility of using DWI for pre-
treatment predicting responders from non-responders in
patients with uterine cervical cancer that undergoing CCR.
Meanwhile, we also found that a few tumors did not re-
spond favorably to CCR despite having lower pretreatment
Fig. 2 Graph shows that comparison of percentage ADC change (γADC) between CR and PR at each time point. Mean value was labeled at the
top of the bar. There was no significant difference in γADC at postT1 (P = 0.286) or postT2 (P = 0.357), while γADC in CR group was significantly
greater than that of PR at postT3 (P = 0.007), postT4 (P = 0.001), and postT5 (P = 0.019)
Fig. 3 Graph shows that the ROC curve for predicting the early
treatment response by using γADC. With the cut-off value of 35.4 %,
the sensitivity and specificity for predicting tumor response group of
CR were 100 % and 73.1 % respectively
Table 3 Comparison of tumour diameter during treatment
between CR and PR
CR(mm) PR(mm) t p
PostT1 42.200 ± 6.590 45.385 ± 16.037 −0.509 0.614
PostT2 41.186 ± 6.228 42.638 ± 16.812 −0.222 0.826
PostT3 40.229 ± 6.187 39.246 ± 17.634 0.144 0.887
PostT4 23.957 ± 9.907 29.408 ± 17.094 −0.802 0.429
Liu et al. Radiation Oncology  (2015) 10:185 Page 6 of 8
ADC values. The hypothesis to explain this is that, necrosis
within a tumor may not always be associated with a high
ADC. In theory, coagulative necrosis without tumor cell li-
quefaction may not increase the ADC [13]. It is therefore
not adequate to use only pretreatment ADC value for
response prediction since it may bring about bias. It would
be preferable to have an early assessment during the course
of treatment which offered a window of opportunity to
optimize or alter the treatment plan in those patients who
are not undergoing a satisfactory response.
Effective anticancer treatment results in tumor lysis,
loss of cell membrane integrity, an increased extracellu-
lar space with a subsequent reduction in tumor cell
density, which facilitates water molecule diffusion [24].
Decreases in tumor cellularity will ultimately lead to re-
duction in tumor size, and this reduction in tumor size
can be expected after 2–3 cycles of systemic treatment,
which usually is between 6 and 12 weeks after start of
treatment [17]. In the present study, we observed an in-
crease in tumor ADC value for both group CR and PR
after treatment, a finding consistent with other studies
[12, 25–27]. For both group CR and PR, significant alter-
ations from the baseline value were noted for ADC value
at 3 days after therapy, while changes in the measurement
of the longest tumor diameter only achieved a borderline
significance compared to baseline at 1 month after ther-
apy. These data confirm that changes in ADC values pre-
cede changes in tumor size, since early after start of
treatment changes in cellularity and necrosis may already
occur. Thus it seems plausible that DWI had a potential
ability to provide an early marker for treatment efficacy
regarding microstructure changes, which may precede sig-
nificant conventional morphologic alterations.
Tumor heterogeneity is seen, not just from patient to
patient, but within the same primary tumor mass. It
would be advantageous to accurately predict a tumor’s
behavior and the time window for early detection of
tumor response after the start of treatment is a key issue.
Our study found that the γADC of CR was significantly
higher than PR at postT3, postT4, and postT5; linear
positive correlations were found between γADC and the
percentage size reduction of tumor after 2 months of
therapy at the time of postT1, postT2, postT3, postT4,
and post T5. These results suggested that elevated ADC
values may reflect the early changes within the tumor
after CCR. Significantly increased ADC value after CCR
may indicate chemosensitivity, however, a minute change
in tumor ADC values might indicate a less satisfactory
outcome or even a therapeutically unresponsive tumor,
which was in line with previous results [26]. By setting up
multiple time points to explore the serial change of ADC
within the tumor, we found that the optimal time window
for early detection of tumor response is the day of 14 after
the therapy initiated, which confirmed the previous find-
ings [26, 28, 29]; meanwhile, we found that γADC could
be served as a representative and sensitive index for re-
sponse assessment. With the cut-off value of 35.4 %, the
sensitivity and specificity for determining the treatment
response were 100 % and 73.1 % respectively. This would
provide an opportunity to adjust individual treatment regi-
mens more rapidly, and allow patients to receive the most
appropriate treatment for their specific case, sparing them
the unnecessary morbidity, expense, or delays in the initi-
ation of effective treatment.
Our study has several limitations. First, the patient
population is relatively small, further studies with a large
number of patients are needed to confirm our prelimin-
ary results. Furthermore, we could not evaluate the exact
pathological mechanism of ADC incensement during
CCR. Third, tumor response is only based on tumor
measurement on T2 weighted MR images at 2 months
of therapy. The follow up time is relatively short, and cy-
tology is not considered as part of the response evalu-
ation at this time point.
Conclusions
On the basis of our preliminary study, we conclude that it
is feasible to use DWI as a non-invasive, radiation-free
method to predict and monitor the early treatment re-
sponse in patients with uterine cervical cancer to CCR.
The day of 14 after CCR initiated can be used as the opti-
mal time window and γADC as a reliable biomarker for
early detection of tumor response, before it is clinically
obvious using standard imaging modality. Early prediction
of high risk to fail ongoing conventional therapy at this
early time point can provide an opportunity for clinicians
to change the initial therapy to more aggressive treatment
regimens such as radiation dose intensification in time.
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